Author

U. Nayar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:whole-exome sequencing· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. G. Waks· 2 shared E. P. Winer· 2 shared K. J. Kowalski· 2 shared N. U. Lin· 2 shared N. Wagle· 2 shared O. Cohen· 2 shared P. Mao· 2 shared S. A. Wander· 2 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. G. Waks

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

bioRxiv · Nov 28, 2019Cancer Biology

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski, J. G. Kusiel, J. E. Buendia-Buendia, M. S. Cuoco, P. Exman, S. A. Wander, A. G. Waks, U. Nayar, J. Chung, S. Freeman, O. Rozenblatt-Rosen, V. A. Miller, F. Federica Piccioni, , N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

bioRxiv · Oct 7, 2019Cancer Biology